Navigation Links
Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
Date:12/20/2007

New Board Member Brings Life Sciences Tools Experience to the Leader in

Cellular Bioenergetic Profiling

N. BILLERICA, Mass., Aug. 10 /PRNewswire/ -- Seahorse Bioscience, the leading provider of tools for real-time measurement of cellular bioenergetics in microplates, announced today that former Molecular Devices executive Joseph Keegan has been appointed to the company's Board of Directors. In this position, Keegan will apply his successful business experience in the life sciences industry to accelerate the growth of Seahorse Bioscience's novel technology for profiling cell metabolism.

"As the company moves into its next phase of growth, it will require a strong understanding of this market," said Jay Teich, Seahorse Bioscience's CEO. "Joe's tremendous success in building Molecular Devices, combined with his extensive labware experience makes him an ideal addition to our Board."

Keegan brings more than 25 years of experience managing life science tools businesses. As CEO of Molecular Devices, he developed a strategy combining internal growth with acquisitions to build the dominant supplier of detection solutions for drug discovery, clinical and research applications. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture. Prior to Becton Dickinson, Keegan was Vice President of Microscopy and Scientific Instruments Division of Leica, Inc.

"Seahorse has developed a 'stethoscope for living cells.' The ability to measure cell metabolism in a truly non-invasive way has very broad applications," said Keegan. "Drawing on my experience with both instrument and labware businesses, I look forward to helping Seahorse grow a successful business in a field that I understand very well."

About Seahorse Bioscience

Seahorse Bioscience is changing cancer, obesity and diabetes drug discovery programs the world over. Seahorse headquarters are located in North Billerica, Massachusetts. For more information, please visit http://www.seahorsebio.com.

Media Contact:

Cheryle Cushion

Seahorse Bioscience

(978) 671-1697

ccushion@seahorsebio.com


'/>"/>
SOURCE Seahorse Bioscience
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- According to a report by Transparency Market Research ... to the presence of a large pool of participants; however, only ... and Sigma-Aldrich, compete with each other in this market. With Proliant ... 76% of this market in 2016.  ... As of now, a large number of vendors ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
Breaking Biology Technology:
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
Breaking Biology News(10 mins):